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Guillain-Barré- Adding Insult to Injury
Casey Hudnall, RN, BSN, SCRN
Otterbein University, Westerville, Ohio
Introduction

Signs & Symptoms

Guillain-Barré syndrome (GBS) is
described as an acute peripheral
neuropathy causing limb asthenia, or
weakness, that progresses over a short
period of time (Lehmann, Hughes,
Kieseier, & Hartung, 2012). GBS is
thought to be immune mediated,
generally triggered by a prior viral or
bacterial infection (Blum & McCombe,
2014). Rapid diagnosis and treatment of
any neurologic condition is paramount to
the
recovery
of
the
individual
experiencing the assault. GBS was once
thought of as a singular disease, but has
since been distinguished as many
subgroups and with varying diagnostic
criteria. The most common subgroups
are acute inflammatory demyelinating
polyradiculoneuropathy (AIDP) and
acute motor axonal neuropathy (AMAN),
and Miller Fisher Syndrome (MFS) (Blum
& McCombe, 2014).

Symptoms tend to appear within the first 2 to
28 days, depending on the precipitating event
(Kopytko & Kowalski, 2014). Classic diagnostic
criteria and clinical presentation is as follows:

It is strongly suggested that the risk of
developing GBS is increased by a host of
factors including familial genetics,
particular pathogen exposure and certain
polymorphisms (Rinaldi, 2013). Recent
attention paid to GBS has been associated
with the H1N1 vaccine. However, studies
conducted between 2015 and 2016
suggest an increased incidence of disease
associated with the Zika virus (CaoLormeau, et al., 2016).
When the
peripheral blood of patients with GBS
have been examined, it reveals
abnormalities in T cells, antibodies and
gene expression (Blum & McCombe,
2014).
Even with rapid treatment,
approximately 20% of patients are left
with severe disability (Kuwabara, 2004).









Progressive motor weakness
•
More than one limb
•
Relative symmetry
•
Over a period of days, up to
4 weeks
Areflexia
•
Universal
(classic
presentation)
•
Distal
Areflexia
with
knee/bicep
hyporeflexia
(variable presentation)
Autonomic dysfunction
•
Tachycardia
•
Postural hypotension
•
Hypertension
•
Vasomotor symptoms
Afebrile

Diagnostic Testing &
Criteria
In order to diagnose Guillain-Barré and the
correct subtype, the following diagnostic
testing must occur and results verified by the
appropriate practitioners.

•


•

Lumbar Puncture
Cerebrospinal Fluid
•
Increased CSF protein
•
Fewer than 10 mononuclear
leukocytes
Electrodiagnostics
Electromyography or Nerve Conduction
Studies
•
Slowed or blocked nerve
conduction

Image 1. Anatomy of a nerve cell. (Charand, 2000)

Underlying Pathophysiology
Guillain-Barre syndrome is described as “an
acquired
neuropathy
characterized
by
inflammation of peripheral nerves,” (Blum,
Csurhes, Reddel, Spies, & McCombe, 2013, p. 92).
Varying subtypes are mediated by different
inflammatory responses. The pathophysiology of
GBS ranges from antibody mediated disease to
macrophage and T cell instigated destruction of
peripheral nerve cells (Blum, Csurhes, Reddel,
Spies, & McCombe, 2013).
T-cell receptors recognize antigens presented
by HLA molecules and immune reactions are
influenced by variations in T-cell genetics (Blum
& McCombe, 2014). Depending on the subtype of
GBS, peripheral nerve cells are presented to Tcells with the help of CD-1, CD-4 or CD-1
polymorphisms (Blum & McCombe, 2014).

Natural killer cells are lymphocytes that play
an important role through chemokines and
cytokines. Killer immunoglobulin-like receptors
(KIR) are the largest group of natural killer (NK)
receptors and exhibit roles in both inhibitory and
activating processes (Blum, Csurhes, Reddel,
Spies, & McCombe, 2013). KIR’s are found on the
surface of many NK cells but also on CD4+ and
CD8+ T lymphocytes (Blum, Csurhes, Reddel,
Spies, & McCombe, 2013). The importance of an
alteration in the KIR/HLA combinations in GBS is
the key to suggestions that innate immunity plays
a significant role in the disease process.
The details of the pathophysiology vary by
subtype. AIDP is the most common variant
accounting for 85% of the cases and is caused by
macrophage
attraction
to
the
myelin
sheath
(Panesar,
2014) .
AMAN is
most commonly seen
following
infection
with campylobacter
jejuni (figure 2) and
is associated with
macrophage invasion
of the node of
Ranvier
(Panesar,
2014) . MSF cases
present with positive
anti-GQ1b antibodies
96% of the time but
underlying
pathophysiology
is
not
completely
understood (Panesar,
2014) .
.

Implications for
Nursing

Nursing can make a difference in the recovery
of their patients by understanding the clinical
presentation, anticipating potential complications
and attending to the specialized needs of the
patient during the acute and recovery phase of
illness. Symptoms can range in severity from
mild weakness and paresthesia to total paralysis
requiring mechanical ventilation. Complications
can include compromised skin integrity due to
limited mobility, respiratory infection due to
prolonged intubation coupled with impair
swallowing, and manifestations of depression due
to emotional distress. Mortalities associated with
GBS are generally secondary to respiratory
processes.
While the clinical care a patient receives is
important, emotional support and education
regarding disease process are equally necessary.
While motor function is significantly impacted by
the pathophysiology of the disease process,
cognitive function remains intact. Communication
to the patient regarding what care is being
provided, why and by whom is especially
important to this patient population to support
their emotional well-being.
The recovery phase of illness can last up to 18
months, with some patients having permanent
disability.
 Appropriate Nursing Interventions
•
Turning and repositioning at regular
intervals
•
Cough and deep breathing exercises
•
Thorough skin care
•
Oral and eye care
•
Passive range of motion
•
Provide emotional support as needed

Significance of
Pathophysiology
Overall, GBS is thought to be a disease due to mimicry between pathogens
expressed on antigens and those on peripheral nerves. The body identifies
“self” as foreign due to recent exposure to an antigen with similar properties
and initiates the inflammatory response. With current research however, no
specific HLA has been identified (Blum, Csurhes, Reddel, Spies, & McCombe,
2013). In demyelinating diseases, autoantibodies bind to myelin, triggering
complement activation and mobilization of macrophages (Pasanen, 2015). In
axonal disorders, the immune response occurs at the nodes of Ranvier, rather
than the myelin sheath (Pasanen, 2015). Gangliosides appear to be the
primary target in axonal disorders, and specific ganglioside antibodies have
been identified in as many as 80% of patients (Pasanen, 2015). Specific
targets for demyelinating syndromes have been more difficult to identify due
to the nonspecific nature of macrophages.
Image 2. Pathophysiology of C. Jejuni associated GBS (van den Berg, et al., 2014)

Conclusion

References, cont.

Guillain-Barre syndrome diagnosis, treatment
and management of relapse requires a
multidisciplinary approach, supportive care and
early mobility (Pasanen, 2015). Relapses are
common and frequently follow vaccinations or
illness; potentially occurring decades after the
initial insult (Kopytko & Kowalski, 2014). Despite
significant advances that have been made in
treatment, GBS mortality remains steady at 4%15% and thus, early diagnosis, appropriate
treatment and prevention of complications are of
the upmost importance.
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